Vanderbilt-Ingram Cancer Center

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

Retrieved on: 
Tuesday, February 6, 2024

The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.

Key Points: 
  • The trial included a predefined subgroup of patients (26%) who were previously treated with both an immuno-oncology (IO) therapy and a VEGFR TKI.
  • “For patients with relapsed or refractory advanced renal cell carcinoma, long-term progression-free survival is a vital measure of the value of anticancer therapy,” commented Michael Bailey, President and CEO of AVEO Oncology.
  • The trial randomized 350 patients to receive FOTIVDA (1.5 mg once daily) or sorafenib (400 mg twice daily).
  • The intent-to-treat (ITT) population included 175 patients in each arm; the safety population included 173 patients in the FOTIVDA arm and 170 in the sorafenib arm.

Groundbreaking Early-Age Onset Colorectal Cancer Think Tank Aims to Transform Colorectal Cancer Outcomes

Retrieved on: 
Wednesday, November 29, 2023

On December 1, 2023, co-hosted with Vanderbilt-Ingram Cancer Center, Fight CRC will leverage innovation and collaboration by convening leading researchers, medical professionals, and emerging scientists at the Early-age Onset Colorectal Cancer (EAO CRC) Think Tank, with a singular objective: to save young lives from colorectal cancer.

Key Points: 
  • On December 1, 2023, co-hosted with Vanderbilt-Ingram Cancer Center, Fight CRC will leverage innovation and collaboration by convening leading researchers, medical professionals, and emerging scientists at the Early-age Onset Colorectal Cancer (EAO CRC) Think Tank, with a singular objective: to save young lives from colorectal cancer.
  • The EAO CRC Think Tank is an extension of Fight CRC's Path to a Cure initiative , aiming to mobilize colorectal cancer champions nationwide, engage them in the scientific research process, and advocate for colorectal cancer research funding while effectively communicating research findings to the public.
  • In response, Fight CRC has taken proactive measures by establishing the EAO CRC Think Tank and forming strategic partnerships with leading experts in the colorectal cancer medical community.
  • Fight CRC President Anjee Davis states, " We are thrilled to be convening the Early-age Onset Colorectal Cancer Think Tank, uniting the foremost experts in colorectal cancer research.

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Sunday, December 10, 2023

The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • The Company is investigating P-BCMA-ALLO1 in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).
  • We are excited to have taken this first step with our early P-BCMA-ALLO1 clinical results.
  • They inspire us to further develop P-BCMA-ALLO1 in partnership with Roche, and to continue advancing our entire allogeneic TSCM cell-based CAR-T portfolio."
  • Title: Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Session Title: 704.

Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

Retrieved on: 
Thursday, November 2, 2023

Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9.

Key Points: 
  • Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9.
  • The approval enables initiation of the clinical development program for ZH9 in the U.S., focusing on patients with non-muscle invasive bladder cancer.
  • "The FDA’s approval of our IND application is an important milestone and a clear recognition of the preclinical data already generated for ZH9,” stated Prokarium’s CEO, Kristen Albright, PharmD.
  • Dara brings over two decades of experience in biotech and large pharma.

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

Retrieved on: 
Thursday, November 2, 2023

After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.

Key Points: 
  • After regional regulatory approvals, GE HealthCare plans to commercialize the models for use both in pharmaceutical drug development and for clinical decision support.
  • To develop the AI models, GE HealthCare and VUMC retrospectively analyzed and correlated the immunotherapy treatment response of thousands of VUMC cancer patients, with their deidentified demographic, genomic, tumor, cellular, proteomic, and imaging data.
  • “These results are a promising development in the journey towards precision care, selecting treatment pathways based on the individual patient’s likely response.
  • The AI models are an integral part of GE HealthCare’s immuno-oncology development portfolio which includes the development of novel PET tracers.

Susan G. Komen® Nashville MORE THAN PINK Walk Returns to Raise Funds for Breast Cancer Patient Care Services and Financial Assistance Programs

Retrieved on: 
Thursday, September 7, 2023

NASHVILLE, Tenn., Sept. 7, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, will hold an in-person MORE THAN PINK Walk to raise critical funds that support breast research and patient care services to better serve those impacted by the disease.

Key Points: 
  • NASHVILLE, Tenn., Sept. 7, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, will hold an in-person MORE THAN PINK Walk to raise critical funds that support breast research and patient care services to better serve those impacted by the disease.
  • "We are excited to provide a space for the breast cancer community to gather and raise funds to end this disease," said Joshua Daniel, State Executive Director at Susan G. Komen.
  • "This event helps raise critical funds for patient care programs including Komen's Patient Care Helpline, which helps provide financial assistance to those impacted by the disease, and Stand for H.E.R.
  • A portion of the proceeds from each ticket sold will be donated to Komen to aid in the fight against breast cancer.

Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Retrieved on: 
Monday, July 24, 2023

and WILMINGTON, Del., July 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.

Key Points: 
  • and WILMINGTON, Del., July 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced positive topline data from the pivotal AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy.
  • Based on these results, and pending agreement from the U.S. Food and Drug Administration (FDA), Syndax and Incyte intend to submit a Biologics License Application (BLA) to the FDA by year-end 2023.
  • "Today marks an important day not only for Syndax and Incyte, but, more importantly, for patients suffering from chronic GVHD," said Michael A. Metzger, Chief Executive Officer of Syndax.
  • These results underscore our belief that axatilimab could provide a valuable and highly differentiated therapeutic option for this devastating disease.

Obsidian Therapeutics Announces Dr. Madan Jagasia as Chief Executive Officer and Other Leadership Appointments

Retrieved on: 
Tuesday, May 23, 2023

Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.

Key Points: 
  • Obsidian Therapeutics Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the appointment of Madan Jagasia, M.D., M.S., as Chief Executive Officer.
  • Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC.
  • Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center.
  • Dr. Norkunas is an experienced biotechnology executive, currently serving as Chief Financial Officer at Generation Bio.

Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

Retrieved on: 
Monday, May 8, 2023

HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a virtual Key Opinion Leader (KOL) event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET.

Key Points: 
  • HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced it will host a virtual Key Opinion Leader (KOL) event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET.
  • The event will feature oncology experts Katherine Fuh, MD, PhD (UCSF Division of Gynecologic Oncology), who will discuss batiraxcept as a potential treatment for ovarian cancer, and Katy Beckermann, MD, PhD (Vanderbilt-Ingram Cancer Center; Vanderbilt University Medical Center), who will provide an overview of batiraxcept as a promising treatment for kidney cancer.
  • The Aravive leadership team will provide a company update and overview of the commercial opportunity and future directions.
  • Batiraxcept has been granted Orphan Drug Designation by the European Commission for platinum-resistant recurrent ovarian cancer.

LUNGevity Announces Pierre Massion Young Investigator Awards for Early Detection Research

Retrieved on: 
Thursday, March 23, 2023

WASHINGTON, March 23, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is honored to announce the recipients of the Pierre Massion Young Investigator Award for Lung Cancer Early Detection Research.

Key Points: 
  • WASHINGTON, March 23, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is honored to announce the recipients of the Pierre Massion Young Investigator Award for Lung Cancer Early Detection Research.
  • This research program was created in memory of Pierre Massion, MD, LUNGevity's first Scientific Advisory Board member and a leader in the lung cancer space, to support underrepresented junior faculty members in the field of lung cancer early detection research.
  • LUNGevity is supporting the following researchers and their early detection studies with the Pierre Massion Young Investigator Award for Lung Cancer Early Detection Research:
    Dr. Benjamin's research focuses on improving the rates of lung cancer screening.
  • This award program combines his passions for mentoring young investigators in early detection research and for eradicating health disparities.